Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Accured Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Accured Expenses for 16 consecutive years, with -$271000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 1835.71% to -$271000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1000.0, a 100.2% increase, with the full-year FY2024 number at -$1.8 million, down 241.3% from a year prior.
  • Change in Accured Expenses was -$271000.0 for Q3 2025 at Harvard Bioscience, down from $302000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.6 million in Q3 2021 to a low of -$4.5 million in Q4 2021.
  • A 5-year average of -$250473.7 and a median of -$120000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 2622.22% in 2022, then soared 1459.33% in 2024.
  • Harvard Bioscience's Change in Accured Expenses stood at -$4.5 million in 2021, then surged by 121.99% to $980000.0 in 2022, then crashed by 122.96% to -$225000.0 in 2023, then plummeted by 567.56% to -$1.5 million in 2024, then surged by 81.96% to -$271000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Change in Accured Expenses are -$271000.0 (Q3 2025), $302000.0 (Q2 2025), and $1.5 million (Q1 2025).